|
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial of CTS-1027 in Combination With Pegylated Interferon
SAN DIEGO, Jan.28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys) and ribavirin (Copegus) in refractory HCV patients.
|
|
|
Human Genome calls hepatitis drug sleeper product
* Zalbin may take big market share from top interferons * Less-frequent dosing could give Zalbin edge * Annual $2 bln interferon market to grow with Zalbin * Could launch both Zalbin, Benlysta this year NEW YORK, Feb 9 (Reuters) - As Human Genome Sciences Inc...
|
|
|
Novartis buys rights to Debiopharm's hep C drug
Novartis has gained exclusive rights to develop a potential first-in-class hepatitis C treatment from fellow Swiss firm Debiopharm.The antiviral agent in question is called Debio 025 (alisporivir). It is the first in a new class of drugs called cyclophilin...
|
|
|
Hepatitis C self-care
If you have hepatitis C your doctor needs to keep close watch on your liver function.iStockphoto.com/Lilli Day Also on the Web myOptumHealth.com tools More from myOptumHealth More>> Health More>> Latest Health News More>> Content provided...
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavir
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus HCV 2010 FEB 8 - (NewsRx.com) Conatus Pharmaceuticals Inc.announced the initiation of a Phase II...
|
|
|
New Animal Model for Evaluating Antiviral Agents Against the SARS Virus Indicates Potential Effect o
PHILADELPHIA, Feb.8, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (the 'Company') reported a recent study, published in the December 20th issue of Virology (2009) by a consortium of researchers at Utah State University and the University of North...
|
|
|
New Animal Model for Evaluating Antiviral Agents Against the SARS Virus Indicates Potential Effect of Ampligen
PHILADELPHIA, Feb.8, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the 'Company') reported a recent study, published in the December 20th issue of Virology (2009) by a consortium of researchers at Utah State University and the...
|
|
|
Hepatitis C Virus Therapy - Scientists at Vertex Pharmaceuticals Inc. discuss research in hepatitis C virus th
Learn more about a six-week, no-risk free trial of Hepatitis Weekly We're a pay-per-view site for premium content.If you'd like to purchase this article, it's only $3.00. Scientists at Vertex Pharmaceuticals Inc. discuss research in hepatitis C virus...
|
|
|
Telaprevir Update- FDA filing second half of 2010
Vertex Pharmaceuticals Reports 2009 Financial Results and Highlights Recent Progress in Hepatitis C and Cystic Fibrosis Development Programs -HCV: New Drug Application planned for telaprevir in second half of 2010; increasing investment in commercialization and...
|
|
|
Telaprevir Update- FDA filing second half of 2010
Vertex Pharmaceuticals Reports 2009 Financial Results and Highlights Recent Progress in Hepatitis C and Cystic Fibrosis Development Programs -HCV: New Drug Application planned for telaprevir in second half of 2010; increasing investment in commercialization and...
|
|
|
Cell-Culture And Animal Tests Show Antiviral Could Provide Protection Against HIV, Ebola, Hepatitis C, Herpes
The development of antibiotics gave physicians seemingly miraculous weapons against infectious disease.Effective cures for terrible afflictions like pneumonia, syphilis and tuberculosis were suddenly at hand. Moreover, many of the drugs that made them...
|
|
|
A glimpse of future hepatitis C virus treatment paradigms - telaprevir
Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourliere M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S; PROVE2 Study Team.Collaborators (28) L Benhamou Y,...
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated ...
Conatus Pharmaceuticals announced the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys) and ribavirin (Copegus) in refractory HCV patients SAN DIEGO, CA, USA | January 28, 2010 | Conatus...
|
|
|
Re-treatment of HIV/HCV Coinfected Patients with Pegylated Interferon plus Ribavirin
Approximately half of people with chronic hepatitis C virus (HCV) infection -- and a somewhat higher proportion of HIV/HCV coinfected people -- do not attain SVR (continued undetectable HCV viral load 24 weeks after completing treatment) with a first course of...
|
|
|
Romark Laboratories initiates enrollment in influenza trial
(Datamonitor via COMTEX) Romark Laboratories, a biopharmaceutical company, has initiated enrollment of patients in a clinical trial of Alinia for treating acute uncomplicated influenza including illness caused by the currently circulating H1N1 strain.The...
|
|
|
Romark Laboratories initiates enrollment in influenza trial
(Datamonitor via COMTEX) -- Romark Laboratories, a biopharmaceutical company, has initiated enrollment of patients in a clinical trial of Alinia for treating acute uncomplicated influenza including illness caused by the currently circulating H1N1 strain.The...
|
|
|
Conatus Pharma begins phase-II trial of pegylated interferon & ribavirin combo to treat HCV
_ Conatus Pharma begins phase-II trial of pegylated interferon & ribavirin combo to treat HCV.
|
|
|
Study shows antiviral drugs could offer protection against HIV, Ebola, herpes and hepatitis C
The development of antibiotics gave physicians seemingly miraculous weapons against infectious disease.Effective cures for terrible afflictions like pneumonia, syphilis and tuberculosis were suddenly at hand. Moreover, many of the drugs that made them...
|
|
|
Study shows antiviral drugs could provide protection against HIV, Ebola, herpes and hepatitis C
The development of antibiotics gave physicians seemingly miraculous weapons against infectious disease.Effective cures for terrible afflictions like pneumonia, syphilis and tuberculosis were suddenly at hand. Moreover, many of the drugs that made them...
|
|
|
FDA Warns of Serious Liver Disorder Associated With Use of Didanosine
-- The US Food and Drug Administration (FDA) is alerting healthcare professionals about a rare, but serious, complication in the liver known as non-cirrhotic portal hypertension in patients using didanosine (Videx or Videx EC).The FDA became aware of cases...
|
|
|
Compound found that targets wide range of viruses
GALVESTON, Texas The development of antibiotics gave physicians seemingly miraculous weapons against infectious disease.Effective cures for terrible afflictions like pneumonia, syphilis and tuberculosis were suddenly at hand. Moreover, many of the drugs...
|
|
|
Conatus Pharmaceuticals initiates Phase II hepatitis trial
Conatus Pharmaceuticals, a specialty pharmaceutical company, has initiated a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon and ribavirin in refractory hepatitis C virus, or HCV, patients.Conatus Pharmaceuticals...
|
|
|
Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection
Chien RN et al.Occult HBV infection in CHC patients is rare. The biochemical and virological responses to combined PEGIFN and RBV therapy might be similar in CHC patients with or without occult HBV infection. Therapeutic effects of pegylated interferon...
|
|
|
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavir
SAN DIEGO, Jan.28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys) and ribavirin (Copegus) in refractory HCV patients.
|
|
|
Report on hepatitis B & C market dynamics in China, South Korea, Taiwan and Turkey
Research and Markets (http://www.researchandmarkets.com/research/65d3a4/stakeholder_insigh) has announced the addition of the "Stakeholder Insight: Hepatitis B & C in Asia - China, South Korea, Taiwan and Turkey" report to their offering.Stakeholder...
|
